Loading…
← CockpitCompetitor Analysis › HIMS Hims & Hers Health, Inc. Class AOpen in the cockpit ↗

Hims & Hers Health, Inc. Class AHIMSCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services

Direct-to-consumer telehealth platform selling subscription-based treatments for men's/women's health, mental health, weight loss and dermatology.

Momentum laggard 9
Mkt cap
$4.00B
US dollars, full cap
Free float
94%
of shares outstanding
$/day
$358M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-16.9 pp
WACC 14.3%
Hurdle
n/a
no reverse DCF
Next earnings
103 days
1 Mar 2027
Close · USD$17.05
1D-2.9%
1W-18.1%
1M-41.6%
3M-46.5%
6M-26.0%
YTD-47.5%
1Y-52.1%
ATR %11.6%
Beta2.67
52w lowhigh58.4% off high

What Hims & Hers Health does

Direct-to-consumer telehealth platform selling subscription-based treatments for men's/women's health, mental health, weight loss and dermatology.

Customers pay monthly or by plan for medication shipped from its own pharmacies, with the consultation by affiliated clinicians included, so revenue is mostly recurring and depends on subscriber retention and what each subscriber buys. Online advertising drives customer acquisition. Some products are compounded versions of branded drugs, a regulatory-sensitive area.

Products and services

  • Weight loss (GLP-1 and other) programs
  • Sexual health (ED, hair loss)
  • Mental health
  • Dermatology/skincare

Customers

  • Consumers seeking convenient, discreet telehealth

Where it sits in the supply chain

  • Healthcare
  • Telehealth/direct-to-consumer care
  • Online consultation + prescription/OTC…

What could go right

  • GLP-1 weight-loss subscriber growth
  • Cross-sell across health verticals

What could go wrong

  • Regulatory risk around compounded GLP-1 drugs
  • Reliance on paid marketing for subscriber acquisition

Moat: narrow (brand, scale, data). Strong direct-to-consumer brand and marketing scale in a category with growing but not-yet-entrenched telehealth competitors.

Headquarters: San Francisco, California, USA · Founded: 2017 · Employees: 2,442

Named competitors

Hims & Hers Health at a glance

Size Hims & Hers Health (HIMS) is a United States Health Care company (Medical/Nursing Services) with a market value of $4.00B, the 1341st largest of 3,085 United States companies the cockpit tracks. Shares closed at $17.05 on 18 Nov 2026.

Performance Over six months the shares fell 26.0%, against +28.9% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 20 in its peer set.

Growth Revenue grew 29.8% over the last twelve months (peer median +11.3%); the operating margin is -1.4% (peer median 8.9%).

Valuation It trades at 1.7× enterprise value to sales against a peer median of 2.3× (7th cheapest of 21).

Capital Return on invested capital runs 16.9 points below its cost of capital (14.3% WACC).

Credit Hims & Hers Health has 1 bond outstanding ($1.00B).

Short interest Short interest is 23.0% of the free float (30 Oct 2026).

Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026Peer median 130HIMS 71
Six months, rebased to 100: Hims & Hers Health against the median of its 20 peers (local-currency closes).

Hims & Hers Health financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.87B$2.35B$1.48B$872M$527M
Revenue growth—+59%+69%+65%—
Gross profit$1.43B$1.39B$970M$705M$401M
EBITDA$67.5M$176M$85.1M-$23.9M-$61.0M
Net income-$191M$128M$126M-$23.5M-$65.7M
Free cash flow$11.6M$57.4M$198M$47.0M-$33.8M
Capital expenditure$172M$243M$52.8M$26.5M$7.25M
Total debt$1.56B$1.12B$11.3M$9.95M$5.31M

Quarterly statements and history in the cockpit →

Hims & Hers Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%-25%0%+25%MCOV-BBLLNLALPATHLABACHCOPCHLFSTCON002044MDAVAHSHLAZTANEOAGARWALEYE603882EMEISHIMS6-month return →1-month return →
Up and to the right = strong over both horizons. Hims & Hers Health is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%5×10×MCOV-BBLLNLALPATHLAB3774ACHCOPCHLFSTCONRDNT002044AVAHSHLADUSALIF-BNEOAGARWALEYE603882HIMSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hims & Hers Health is the large dot.

Hims & Hers Health competitors and peer comparison

Head to head with its named competitors (HIMS vs TDOC vs LLY vs NOVO-B.CO)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Hims & Hers Health HIMS$4.00B-26%+30%-1%1.7×n/a
Teladoc Health TDOC$1.47B+24%-2%-5%0.7×-6.4%
Lilly (Eli) LLY$1.30T+36%+46%51%15.6×6.5%
Novo Nordisk A/S NOVO-B.CO$177B-6%+6%48%3.9×-0.5%
GoodRx GDRX$1.15B+33%-2%12%1.8×6.3%

How Hims & Hers Health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hims & Hers Health against its 20 peers (data as of 18 Nov 2026)
MeasureHIMSPeer medianRank in peer set
1-month return-41.6%+2.8%lowest of 21
6-month return-26.0%+28.9%3rd lowest of 20
Distance from 52-week high-58.4%-10.5%lowest of 21
Revenue growth (TTM)+29.8%+11.3%3rd highest of 21
Operating margin-1.4%8.9%3rd lowest of 21
EV / Sales1.7×2.3×7th cheapest of 21
ROIC minus cost of capital-16.9 pp+0.0 pplowest of 21
Net debt / EBITDA12.6×2.6×2nd most indebted of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Hims & Hers Health HIMSUnited States$4.00B-26%+30%-1%1.7×n/an/a
Medicover MCOV-B.STSweden$3.87B+21%+3%7%2.0×19.6%+20.2%
BillionToOne BLLNUnited States$4.37B+7%+72%10%9.1×22.8%+71.9%
Dr. Lal PathLabs LALPATHLAB.NSIndia$3.53B+15%+17%24%10.4×32.3%+11.8%
Fameglow 3774.HKHong Kong$4.54Bn/a+36%11%60.4×57.4%+48.4%
Acadia Healthcare ACHCUnited States$3.49B+56%+4%10%1.8×n/an/a
Option Care Health OPCHUnited States$4.75B+43%+4%6%1.0×2.0%+13.2%
Lifestance Health LFSTUnited States$5.24B+79%+23%6%3.3×33.4%+30.4%
Concentra Group Holdings Parent CONUnited States$5.31B+65%+12%17%3.2×3.6%+7.9%
RadNet RDNTUnited States$5.66B+32%+21%5%3.1×38.8%+13.7%
Meinian Onehealth Healthcare 002044.SZChina$2.60B-27%-4%9%2.2×4.2%+5.7%
Pediatrix Medical MDUnited States$2.41B+37%+2%12%1.3×-4.4%+2.0%
Aveanna Healthcare AVAHUnited States$2.37B+41%+17%12%1.4×7.7%+10.2%
Sonic Healthcare SHL.AXAustralia$6.87B+6%+14%9%1.4×9.1%+3.5%
Addus HomeCare ADUSUnited States$2.25B+29%+12%11%1.5×4.0%+13.2%
AddLife ALIF-B.STSweden$2.13B+15%+2%8%2.5×21.1%+14.6%
Azenta AZTAUnited States$2.03B+162%+5%-2%2.8×38.0%+3.9%
NeoGenomics NEOUnited States$1.98B+72%+11%-6%2.9×n/an/a
Dr. Agarwal's Health Care AGARWALEYE.NSIndia$1.86B+20%+26%15%7.8×43.0%+26.9%
Guangzhou Kingmed Diagnostics 603882.SSChina$1.86B+5%-3%7%1.9×5.4%-6.1%
Emeis EMEIS.PAFrance$1.78B-33%+4%3%1.6×21.2%+8.5%

Hims & Hers Health bonds and credit

Hims & Hers Health has 1 bond outstanding with $1.00B face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Hims & Hers Health's main competitors?
Named competitors: Teladoc Health (TDOC), LifeMD (private or unlisted), Eli Lilly (LLY), Novo Nordisk (NOVO-B.CO), GoodRx (GDRX), WW International (private or unlisted). The cockpit's measured peer set (industry) also includes Medicover (MCOV-B.ST), BillionToOne (BLLN), Dr. Lal PathLabs (LALPATHLAB.NS), Fameglow (3774.HK), Acadia Healthcare (ACHC), Option Care Health (OPCH).
Is Hims & Hers Health expensive compared with its peers?
On ev / sales it trades at 1.7× against a peer median of 2.3×, 7th cheapest of 21 in its peer set.
How has Hims & Hers Health stock performed?
Over six months to 18 Nov 2026 the shares returned -26.0% against +28.9% for the median peer; over one year -52.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.